

# AMSER Case of the Month

## September 2026

25yo F G3P2002 with no PMH (including substance use or exposures) who declined vaccinations presents for further evaluation after abnormal 20wk ultrasound showing echogenic bowel, subjectively prominent lateral ventricles and fetal growth restriction (FGR) with estimated fetal weight (EFW) <10<sup>th</sup> %ile). Cell free DNA screening: Low-risk, female.

Bailey Hoglin, MPH, MS4 University of Utah

Anne M. Kennedy, MB, BCh, BAO University of Utah

April M. Griffith, MD University of Utah

# ACR Appropriateness Criteria

**Variant: 3** Second and third trimester screening for abnormal finding on ultrasound: soft markers. Next imaging study.

| Procedure                                       | Appropriateness Category | Relative Radiation Level |
|-------------------------------------------------|--------------------------|--------------------------|
| US pregnant uterus transabdominal detailed scan | Usually Appropriate      | 0                        |
| US pregnant uterus transabdominal follow-up     | Usually Appropriate      | 0                        |
| US echocardiography fetal                       | May Be Appropriate       | 0                        |
| MRI fetal without and with IV contrast          | Usually Not Appropriate  | 0                        |
| MRI fetal without IV contrast                   | Usually Not Appropriate  | 0                        |

Source: American College of Radiology. ACR Appropriateness Criteria®: Second and Third Trimester Screening for Fetal Anomaly. Reston, VA: American College of Radiology; 2020. Accessed May 16, 2026. <https://acsearch.acr.org/docs/3102400/Narrative/>

# Imaging Ordered: Detailed anatomic US

## UA Doppler for FGR


### Findings at 27w5d


- Severe FGR ,now EFW< 1% and suboptimal interval growth
- Normal amniotic fluid volume
- UA doppler variable, some elevated systolic/diastolic (SD) ratios
- Liver and adrenal calcifications
- Enlarged cisterna magna (11.4mm) with small cerebellum
- Periventricular calcifications



BPD : Biparietal diameter  
 HC: Head circumference  
 Pctl: Percentile for gestational age (GA)

|      |           |    |
|------|-----------|----|
| BPD  | 6.18      | cm |
| GA   | 25w1d±15d |    |
| Pctl | 0.73*     | %  |
| HC   | 23.20     | cm |
| GA   | 25w2d±14d |    |
| Pctl | 4.68      | %  |





BPD : Biparietal diameter  
HC: Head circumference




|      |           |    |
|------|-----------|----|
| BPD  | 6.18      | cm |
| GA   | 25w1d±15d |    |
| Pctl | 0.73*     | %  |
| HC   | 23.20     | cm |
| GA   | 25w2d±14d |    |
| Pctl | 4.68      | %  |


Z score -2.7

Z score -3.8

Diffuse periventricular calcifications  
Microcephaly

Enlarged cisterna magna  
(11.4mm)  
Small cerebellum







Sagittal left




Axial abdomen



Sagittal right




Sagittal right



Sagittal left

Adrenal calcifications



Sagittal right

Axial abdomen



Liver calcifications

Hepatomegaly: Liver length 95<sup>th</sup> %ile for GA



Sagittal right

# ACR Appropriateness Criteria

**Variant: 4** Second and third trimester screening for abnormal finding on ultrasound: major anomalies. Next imaging study.

| Procedure                                       | Appropriateness Category | Relative Radiation Level |
|-------------------------------------------------|--------------------------|--------------------------|
| US echocardiography fetal                       | Usually Appropriate      | 0                        |
| US pregnant uterus transabdominal detailed scan | Usually Appropriate      | 0                        |
| US pregnant uterus transabdominal follow-up     | Usually Appropriate      | 0                        |
| MRI fetal without IV contrast                   | Usually Appropriate      | 0                        |
| MRI fetal without and with IV contrast          | Usually Not Appropriate  | 0                        |

Source: American College of Radiology. ACR Appropriateness Criteria®: Second and Third Trimester Screening for Fetal Anomaly. Reston, VA: American College of Radiology; 2020. Accessed May 16, 2026. <https://acsearch.acr.org/docs/3102400/Narrative/>

# Imaging Ordered: Follow-up Ultrasound


## Findings:

- 30w3d
- Severe fetal growth restriction with EFW 2%
- Elevated SD ratios in the umbilical artery

# Imaging Ordered: Fetal MRI without IV contrast


## Findings:

- Small, dysplastic cerebellum
- Suspected polymicrogyria involving the left cerebral hemisphere
  - Polymicrogyria: a brain development disorder where the surface has too many, excessively small folds (gyri) and a bumpy, thickened cortex with a fuzzy gray-white matter border
- Hippocampal atrophy



Normal age-matched  
images for comparison

H: Cerebeller hemisphere  
V: Vermis  
CM: Cisterna magna




Cortical malformation/  
polymicrogyria

Cerebellar dysplasia

Hippocampal dysplasia

Fetal right



The right sylvian fissure is normally formed with smooth cortex unlike the left where the fissure is abnormal in shape and the cortex has the “bumpy” appearance of polymicrogyria .

Severe loss of **cerebellar tissue** with resultant increase in size of the cisterna magna.  
**Hippocampi** are thin, dysplastic and of abnormally low signal

# Final Diagnosis

Congenital cytomegalovirus infection

# Case Discussion

Congenital CMV (cCMV) infection is the most common congenital viral infection, affecting around 1 in 200 infants in high-income countries and 1 in 71 in low- and middle-income countries.<sup>1,2</sup> Reported prevalence of cCMV is 0.2% to 2.0% (average of 0.64%) of pregnancies.<sup>3</sup> Long-term sequelae including sensorineural hearing loss and neurodevelopmental disability.

CMV infection can be acquired during pregnancy (primary infection) or be a reactivation of a prior CMV infection or a new infection with a different strain of the virus (non-primary infection).<sup>2</sup> Women with primary infection experience a higher transplacental transmission rate (30-40%) in comparison to women with a non-primary infection who experience a low transmission rate (1-2%).<sup>4</sup> Regardless of primary v. non-primary infection, the severity of cCMV is trimester specific with more severe neurologic sequelae occurring more frequently with infection in the first trimester (20–30%) when compared to infection in the second and third trimester.<sup>4</sup>

The most common source of CMV infection in pregnant women is the saliva and urine of young children. The majority of people with active CMV infection are asymptomatic with 10% experiencing symptoms like infectious mononucleosis.<sup>2</sup> Fetal diagnosis of cCMV is made by amniocentesis performed after 17 weeks of gestation and at least 6–8 weeks after the suspected maternal infection.<sup>1</sup>

# Case Discussion

## Ultrasound Findings<sup>5</sup>

- Fetal intracranial calcification
  - mainly periventricular
- Fetal hydrocephalus
- Heterogeneous brain parenchyma
- Microcephaly
- Intraventricular adhesions
- Fetal intrahepatic calcification
- Fetal hepatomegaly
- Fetal growth restriction (FGR)
- Echogenic bowel

## MRI Findings<sup>6</sup>

- White matter hyperintensities
- Ventriculomegaly (unilateral or bilateral)
- Cysts/pseudocysts
- Ventriculitis
- Intraventricular septations/adhesions
- Cortical malformations/polymicrogyria
- Clefts (schizencephaly/porencephaly)
- Cerebellar Hypoplasia/dysplasia
- Hippocampal dysplasia
- Lenticulostriate vasculopathy
- Hepatomegaly, splenomegaly
- Effusions (pericardial, pleural, ascites)
- Skin edema
- Thickened placenta

# Case Discussion

Prenatal treatment for cCMV is controversial. There is ongoing investigation of the role of valganciclovir and CMV hyperimmune globulin in treatment.

The prognosis predictors for infected fetuses are largely based on timing of infection, presence and type of fetal anomalies, and laboratory results.<sup>2</sup> Best next steps are case dependent on fetal findings and goals of care discussions between patients and providers.

# References:

1. Jones CE, Bailey H, Bamford A, et al. Managing challenges in congenital CMV: current thinking. Arch Dis Child. 2023;108(8):601-607. doi:10.1136/archdischild-2022-323809
2. Khalil A, Heath PT, Jones CE, Soe A, Ville YG; Royal College of Obstetricians and Gynaecologists. Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment: Scientific Impact Paper No. 56. BJOG. 2025;132(2):e42-e52. doi:10.1111/1471-0528.17966
3. Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177-e188. doi:10.1016/S1473-3099(17)30143-3
4. Palmetti M, Venturini E, Bartolini L, Chiappini E, Lyall H, Galli L. Congenital CMV infection and central nervous system involvement: mechanisms, treatment, and long-term outcomes. Eur J Pediatr. 2025;184:381. doi:10.1007/s00431-025-06215-4
5. Radswiki T, Ibrahim D, Baba Y, et al. Congenital cytomegalovirus infection. Radiopaedia.org. Published 2010. Last revised October 12, 2021. Accessed May 18, 2026. <https://doi.org/10.53347/rID-12647>
6. Diogo MC, Glatter S, Binder J, Kiss H, Prayer D. The MRI spectrum of congenital cytomegalovirus infection. Prenat Diagn. 2020;40(1):110-124. doi:10.1002/pd.5591
7. Pinninti S, Boppana S. Congenital cytomegalovirus infection diagnostics and management. Dis. 2022;35(5):436-441. doi:10.1097/QCO.0000000000000874